Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(302)
•••
Comment by jojomarchon Jan 30, 2020 9:43am
117 Views
Post# 30619133

RE:RE:RE:RE:RE:RE:RE:The longer the WAIT - The WEIGHTIER THE NEWS

RE:RE:RE:RE:RE:RE:RE:The longer the WAIT - The WEIGHTIER THE NEWS
enriquesuave wrote: I agree with you there Vestor.  After approval they may say something like 2nd treatment maybe given between 6-12 months if patient was cancer free at 6 months giving a 6 month window to retreat rather than at 6 months precisely?  Who knows. The thing is that these are the worst patients who have failed treatment, so it will still be safer to retreat rather than wait too long. Just imho 


So if you are the freshly diagnosed bladder cancer patient , after reviewing the possible treatments what do you tell your doctor(s) ;

  i would prefer the total destruction therapy of TLD 1433 that was used on the worst patients that had failed treatments so that i can  nip it in the bud 

or would you say give me the immuno cocktail therapy .....hummmm

Cheers

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities